Blinatumomab - Amgen

Drug Profile

Blinatumomab - Amgen

Alternative Names: AMG-103; Blincyto; MEDI-538; MT-103

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Micromet Inc
  • Developer Amgen; Astellas Pharma; M. D. Anderson Cancer Center; Merck & Co; Micromet Inc; National Cancer Institute (USA); University of California, Davis
  • Class Antineoplastics; Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action Immunostimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Precursor cell lymphoblastic leukaemia-lymphoma; Mantle-cell lymphoma; B cell prolymphocytic leukaemia; B cell lymphoma; T cell prolymphocytic leukaemia; Chronic lymphocytic leukaemia; Hairy cell leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Precursor B-cell lymphoblastic leukaemia-lymphoma
  • Phase II/III Non-Hodgkin's lymphoma
  • Phase II Diffuse large B cell lymphoma
  • Discontinued Chronic lymphocytic leukaemia

Most Recent Events

  • 25 Sep 2018 Adverse events data from the phase III TOWER trial and the phase I/II Horai trial in Acute lymphoblastic leukaemia released by Astellas Pharma
  • 24 Sep 2018 Registered for Precursor B cell lymphoblastic leukaemia-lymphoma (Second-line therapy or greater) in Japan (IV)
  • 21 Sep 2018 Amgen requests re-examination of the CHMP's negative opinion for marketing authorization of blinatumomab for the treatment of minimal residual disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top